Elypta

Elypta is developing a metabolism-based liquid biopsy platform, which is based on new IVD lab assay kits and artificial intelligence algorithms trained by its clinical database. Elypta proudly sponsors the AURORAX clinical trial series to study the application of its lead indication, renal cell carcinoma, from monitoring recurrence to monitoring treatment response. They are also exploring several other indications to understand the full potential of the Elypta platform.